These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 1435900

  • 1. A less costly regimen of alglucerase to treat Gaucher's disease.
    Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, Gelbart T, Beutler E.
    N Engl J Med; 1992 Dec 03; 327(23):1632-6. PubMed ID: 1435900
    [Abstract] [Full Text] [Related]

  • 2. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH.
    Lancet; 1995 Jun 10; 345(8963):1474-8. PubMed ID: 7769902
    [Abstract] [Full Text] [Related]

  • 3. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.
    Whittington R, Goa KL.
    Pharmacoeconomics; 1995 Jan 10; 7(1):63-90. PubMed ID: 10155294
    [Abstract] [Full Text] [Related]

  • 4. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.
    Zimran A, Elstein D, Kannai R, Zevin S, Hadas-Halpern I, Levy-Lahad E, Cohen Y, Horowitz M, Abrahamov A.
    Am J Med; 1994 Jul 10; 97(1):3-13. PubMed ID: 8030654
    [Abstract] [Full Text] [Related]

  • 5. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R, Goa KL.
    Drugs; 1992 Jul 10; 44(1):72-93. PubMed ID: 1379912
    [Abstract] [Full Text] [Related]

  • 6. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun 10; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 7. Enzyme replacement therapy for Gaucher's disease.
    Beutler E.
    Baillieres Clin Haematol; 1997 Dec 10; 10(4):751-63. PubMed ID: 9497862
    [Abstract] [Full Text] [Related]

  • 8. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A.
    Lancet; 1995 Jun 10; 345(8963):1479-80. PubMed ID: 7769903
    [Abstract] [Full Text] [Related]

  • 9. Gaucher's disease: a review.
    Morales LE.
    Ann Pharmacother; 1996 Apr 10; 30(4):381-8. PubMed ID: 8729893
    [Abstract] [Full Text] [Related]

  • 10. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1.
    Pérez-Calvo J, Giraldo P, Pastores GM, Fernández-Galán M, Martín-Nuñez G, Pocoví M.
    J Postgrad Med; 2003 Apr 10; 49(2):127-31. PubMed ID: 12867687
    [Abstract] [Full Text] [Related]

  • 11. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.
    MacKenzie JJ, Amato D, Clarke JT.
    CMAJ; 1998 Nov 17; 159(10):1273-8. PubMed ID: 9861225
    [Abstract] [Full Text] [Related]

  • 12. [Enzyme replacement therapy: a new treatment concept in Gaucher disease].
    Beck M, Mengel E, Barone R.
    Wien Klin Wochenschr; 1997 Feb 14; 109(3):81-5. PubMed ID: 9139464
    [Abstract] [Full Text] [Related]

  • 13. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease.
    Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, Agosti E.
    Lancet; 1994 Dec 17; 344(8938):1679-82. PubMed ID: 7996964
    [Abstract] [Full Text] [Related]

  • 14. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE.
    N Engl J Med; 1991 May 23; 324(21):1464-70. PubMed ID: 2023606
    [Abstract] [Full Text] [Related]

  • 15. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
    Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebícek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A.
    Lancet; 2000 Apr 29; 355(9214):1481-5. PubMed ID: 10801168
    [Abstract] [Full Text] [Related]

  • 16. Glucocerebrosidase for treatment of Gaucher's disease: first German long-term results.
    Niederau C, Holderer A, Heintges T, Strohmeyer G.
    J Hepatol; 1994 Oct 29; 21(4):610-7. PubMed ID: 7814809
    [Abstract] [Full Text] [Related]

  • 17. Alglucerase for Gaucher's disease: dose, costs and benefits.
    Beutler E, Garber AM.
    Pharmacoeconomics; 1994 Jun 29; 5(6):453-9. PubMed ID: 10147261
    [No Abstract] [Full Text] [Related]

  • 18. The clinical course of treated and untreated Gaucher disease. A study of 45 patients.
    Beutler E, Demina A, Laubscher K, Garver P, Gelbart T, Balicki D, Vaughan L.
    Blood Cells Mol Dis; 1995 Jun 29; 21(2):86-108. PubMed ID: 8846048
    [Abstract] [Full Text] [Related]

  • 19. [Uveitis masquerade syndrome in Gaucher disease. Causal treatment by alglucerase substitution therapy].
    Dann K, Althaus C, Kersten A, vom Dahl S, Sundmacher R.
    Klin Monbl Augenheilkd; 1998 Dec 29; 213(6):358-61. PubMed ID: 10048015
    [Abstract] [Full Text] [Related]

  • 20. [Type I Gaucher's disease: clinical, evolutive and therapeutic features in 8 cases].
    Giraldo P, Pérez-Calvo J, Cortés T, Civeira F, Rubio-Félix D.
    Sangre (Barc); 1994 Feb 29; 39(1):3-7. PubMed ID: 8197516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.